Possession
Check the current annex text, the actual substance and preparation, and any other applicable rule.
Germany · legal orientation
Legal Overview
Ibogaine is not named in the BtMG annexes checked on 6 October 2026. That narrow observation is not a general permission: medicines law, import rules, professional duties and the facts of a particular product or activity can still matter.
01 / Controlled substances
Start with the BtMG annex text
Germany’s Narcotics Act (BtMG) works through its annexes. Annex I lists non-marketable narcotics, Annex II marketable but non-prescription narcotics, and Annex III marketable and prescription narcotics. The current consolidated BtMG text is the appropriate first source for checking whether a named substance appears there.
On the annexes checked on 6 October 2026, “Ibogaine” is not named. Safe wording is therefore: “Ibogaine is not named in the BtMG annexes consulted on 6 October 2026.” It is less precise to say simply that ibogaine is “legal,” because that changes a limited scheduling observation into a broader legal conclusion.
Annex absence is a finding about the BtMG lists, not a complete answer about a product, border movement, supply, or therapeutic use.
Terminology also matters: the statutory category is narrower than ordinary language. For background on the structure of a controlled-substance regime, the controlled substance definition can help distinguish scheduling from every other area of regulation.
02 / Medicines regulation
The AMG may be the next question
Whether a particular item is a medicinal product can depend on its presentation, intended use and pharmacological function. The consolidated Arzneimittelgesetz is the primary text for the medicines-law framework, including the definition of medicinal products and rules relevant to placing medicines on the market.
That means labels, sales language, dosage claims, instructions and the product’s actual characteristics can all matter. A statement that ibogaine is absent from the BtMG annexes does not decide whether an individual preparation triggers AMG questions, nor does it establish authorisation, quality, safety, advertising or supply compliance.
The Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) explains its remit through its official medicines information. Where a commercial description conflicts with a statute, an official authority page, or a court decision, verify the primary material rather than repeating the commercial wording.
03 / Activity changes the analysis
Possession is not the same as supply or use
Legal questions often turn on what is being done, not only on the molecule named on a page. Personal possession, cross-border importation, commercial distribution, advertising, and a purported therapeutic setting can engage different rules and facts. Customs controls may apply at the border even where a BtMG scheduling statement alone does not resolve the matter.
Importation
Border movement adds customs and import questions; product classification can be decisive.
Distribution
Supply, marketing and claims can raise medicines-law and commercial-law issues.
Therapeutic context
Medical practice rules, professional duties and liability remain separate considerations.
The same caution applies when comparing options described elsewhere online. Material about affordable ibogaine treatment or cost of ibogaine treatment in Mexico may discuss other jurisdictions or commercial settings; it cannot establish the German legal position of a particular act or product.
04 / Verification sequence
Use a source hierarchy, not a headline
For a careful check, begin with the current consolidated BtMG annexes, then the AMG and relevant official authority material. If the question turns on a dispute or enforcement point, locate the underlying decision in the federal courts’ published case-law database rather than relying on a summary.
- Record the exact date the annexes and statutory text were checked.
- Quote what the source says—and keep “not named in the annexes” distinct from “permitted.”
- Identify the actual activity: holding, importing, supplying, advertising, or providing a service.
- Check the product presentation and claimed purpose before drawing AMG conclusions.
Our source-checking guidance for Germany explains the same verification discipline in more detail, while the practical risks page separates legal uncertainty from claims that a provider or seller may make.
05 / Context without endorsement
Claims online do not settle German law
Search results may mix legal descriptions with treatment marketing, personal accounts and international comparisons. For example, pages discussing what ibogaine feels like or New Path ibogaine reviews are not substitutes for the German statutory materials used to answer a legal question.
It is equally important not to treat discussion of a condition as proof that a product or service is legally available, authorised, appropriate or safe. Claims connected with ibogaine treatment for depression should be kept separate from the legal status of ibogaine under German law and from any individual medical decision.
For the broader approach behind this page, see the plain-language legal resource and the explanation of how this resource handles uncertainty. Neither replaces advice from a qualified German lawyer for a concrete situation.
Short answers
Frequently raised questions
Is ibogaine listed in the BtMG annexes?
As checked on 6 October 2026, ibogaine is not named in the current BtMG annexes. That observation concerns the annex text. It does not decide questions under medicines, customs, professional or other law.
Does annex absence mean importation or therapeutic use is permitted?
No. Annex absence is not a general permission. Product classification, the AMG, import and customs rules, professional duties and the facts of a specific case may still matter. Questions about purported treatment providers also require care; background about Howard Lotsof does not determine German regulatory requirements.
What is the safest wording to cite?
State the date and scope: “Ibogaine is not named in the BtMG annexes consulted on 6 October 2026.” Avoid converting that sentence into a conclusion about all possession, importation, supply or treatment questions.